The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
To clarify, Suzy has not said there will never be a placing. There isn’t a single CEO who could do that, especially on the AIM. However, it would put Suzy in a very precarious position to announce an EGM with a view to a placing at this stage. She has made some mistakes in the past, the timing of the 10p placing being a significant one. Lessons were learnt from that. Suzy will not make the same mistake again. This is not groundhog day.
No-one knows what income she has achieved from Inaphaea. We know she has considerably reduced Val’s cost base. She has also recently splashed out on an evaluation agreement with StingRay Bio. To quote a fellow investor at that time “it would be ludicrous to make today’s announcement without knowing cash was coming in the short term.”
Furthermore, in the last Q&A, an upbeat Suzy stated she expects a ‘significant update re VAL201” with ”a good degree of certainty” and “if that wasn’t the case we would have advised SHs”. All this on top of the recent Val401 RNS. No RNS has been issued to announce an EGM and no RNS issued to advise of any change to her Val 201 optimism.
The SP recently went up nearly 3-fold on no significant news. Can you imagine what a 201 deal confirmation would do to the SP.
Life comes with no guarantees but to those holding, the odds look pretty stacked in our favour. To use the old, but true, nutmeg “I wouldn’t want to be out of this over the weekend”.
Big Week.
201 = potential 61 million pounds plus royalties plus payments upfront and consultancy fees.
The market cap is too low. This should be worth at least 20p then 201 arrives hopefully takes us to 40-60p range.
The company has deals, assets and value. A great time to buy at these low prices. 201 news on the way so a great opportunity imo.
Not relevant. You don't mention when it goes up and your strikes are not up.
Still up almost 100% over the last few weeks. You will get a few profit takers.
Free options at decent prices so why risk when you don't need to.
If the answer is no then it would not take so long. It could be a takeover somewhere, it might be us. A 50p offer will do nicely for most here.
They must be finalising many things therefore I look forward to a positive outcome shortly.
Latest rns.
Euda merger with Theormrx
“Ken Chen founder and ceo of euda “”we believe Theormrx has STRONG access to capital and a robust pipeline of compounds ….its project portfolio is also pre selected for HIGH upside, with MINIMAL time and cost to reach key monetization milestones ..”
Now. Who do we listen to Ken Chen. Adam hargreaves. Patrick Frankham. Suzy. (Combined)
Or
To porky 🤦♂️
One is not needed if the deal goes ahead
but
2 million at 30p after 201 is a 6% dilution. GDR did this last year 8p to 50p then placing 30p.
PLus lab revenue plus warrants plus 201 cash. Enough to last 3 years.
If not they can get it done at 9/10p for only 1 million plus lab revenue enough to last 12 months but by then get a CLX deal . Simple.
90-95% the merger should be successful and we should rise significantly.
I have done my research!
I know facts!
I deal in analysis!
I know the figures!
Why don’t you put a £10 short on it! If you are so confident! Why don’t you, Porky?
You are all talk! You attack us day and night with imminent placing. But if you believe in your so called analysis, facts and figures then why not short this stock?
You have no answer!
Now shut up! If you can’t back your research then shut up! If anyone here listens to you then they don’t deserve to make money in this stock!
Latest rns.
Euda merger with Theormrx
“Ken Chen founder and ceo of euda “”we believe Theormrx has STRONG access to capital and a robust pipeline of compounds ….its project portfolio is also pre selected for HIGH upside, with MINIMAL time and cost to reach key monetization milestones ..”
Now. Who do we listen to Ken Chen. Adam hargreaves. Patrick Frankham. Suzy. (Combined)
Or
To porky 🤦♂️
Ironmighty
Posts: 498
Price: 12.125
Strong Buy
Recent eventsToday 10:43
It's been a bit of a confusing old time, so here is a recap of the events of the last few weeks...
A group of shareholders wrote to Valirx with a set of questions. A reply in the form of a ultra-bullish recorded Q&A.
Suzy: “We are expecting significant updates from them [TheoremRX] before year end “
Suzy: “We have every indication we that we will be able to put out a substantial update before the end of the year”
A few days later, the empty TheoremRX website created in 2020 was finally updated with content. Just a landing page, but surely not for no reason?
Following that, a press release stating TheoremRX plan to merge with EUDA Health, a Nasdaq listed co.
https://www.morningstar.com/news/globe-newswire/8944265/euda-health-holdings-limited-enters-into-letter-of-intent-for-proposed-merger-with-theoremrx-inc
CEO of EUDA: “We believe TheoremRx has strong access to capital and a robust pipeline of compounds.."
A statement is made that the prospectus is available online. A detailed search reveals the TMT Acquisition Corp SPAC, underwritten by Maxim Group. Maxim Group also happened to be the sole book-running manager for 8i (EUDA). TMT Acquisition prospectus also happens to contain clauses that excludes China from their business dealings. VAL happened to remove China from the TheoremrX exclusivity earlier this year. TMT Acquisition also happens to be funded by several EUDA funders. TMT also happens to have funds of between $60m and $70m.
The merger has a 30 - 45 day window (not too many days left now). A week ago, the EUDA website is then taken offline..
IMO there is too much here for all this to be nothing. In fact, I think the signs look very promising indeed. But SHs are not fools. We know Val will need money in Q1 in the event it all falls through. It is hardly revelatory.
Enjoy your Sunday and GLA.